Joe Ciaffoni serves as Chief Executive Officer of Indivior Pharmaceuticals Inc., a leading biopharmaceutical company focused on innovative treatments for serious unmet medical needs, particularly opioid use disorder. With more than 25 years of experience in the pharmaceutical industry, Ciaffoni has built a distinguished career in commercial leadership and strategic growth. He joined Indivior in 2018 as Chief Commercial Officer, bringing expertise from prior roles including President of U.S. Pharma at Mallinckrodt Pharmaceuticals, where he led commercial operations across a broad portfolio of specialty therapeutics. Earlier, at Purdue Pharma L.P., he advanced through senior positions, including Vice President of U.S. Sales and Marketing, driving the commercialization of novel pain management and addiction therapies. Under Ciaffoni's guidance, Indivior has strengthened its position as a pioneer in addiction medicine, with key products like SUBLOXONE, SUBLOCADE, and PERSERIS achieving significant market penetration and clinical impact. His strategic vision has emphasized expanding access to evidence-based treatments amid the ongoing opioid crisis, resulting in robust revenue growth, successful product launches, and enhanced partnerships with healthcare providers and policymakers. Ciaffoni's leadership has also prioritized operational excellence and innovation, positioning the company for sustained long-term success. As CEO since April 2023, Ciaffoni continues to champion patient-centric initiatives, fostering a culture of accountability and collaboration to address global addiction challenges while delivering strong shareholder value. His deep industry knowledge and proven track record make him a pivotal figure in advancing Indivior's mission to transform lives through transformative therapies.